Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (3): 241-246.DOI: 10.3969/j.issn.1673-8640.2025.03.007
Previous Articles Next Articles
JIA Lingyan1, XIE Shanli1(
), CHEN Ze2
Received:2024-01-14
Revised:2024-11-18
Online:2025-03-30
Published:2025-04-10
CLC Number:
JIA Lingyan, XIE Shanli, CHEN Ze. Relationship between serum miR-370-3p and miR-152-5p expressions and clinical pathological characteristics and prognosis of ovarian cancer patients[J]. Laboratory Medicine, 2025, 40(3): 241-246.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.03.007
| 基因名称 | 正向引物(5' ~3') | 反向引物(5' ~3') |
|---|---|---|
| miR-370-3p | AGCGGGTTTTGCTAGGGC | TAGCGCCTAGGGCATCGATC |
| miR-152-5p | CGACTCGATCGCTCTTCAGAG | AGTAGGCTGCTAGCGCTGC |
| U6 | ATGGTCTTTTCTGATTAGCC | GATTTCGCTCAAGACGTCGA |
| 基因名称 | 正向引物(5' ~3') | 反向引物(5' ~3') |
|---|---|---|
| miR-370-3p | AGCGGGTTTTGCTAGGGC | TAGCGCCTAGGGCATCGATC |
| miR-152-5p | CGACTCGATCGCTCTTCAGAG | AGTAGGCTGCTAGCGCTGC |
| U6 | ATGGTCTTTTCTGATTAGCC | GATTTCGCTCAAGACGTCGA |
| 组别 | 例数 | miR-370-3p | miR-152-5p |
|---|---|---|---|
| 正常对照组 | 108 | 1.00±0.26 | 1.00±0.25 |
| 卵巢癌组 | 108 | 0.75±0.16 | 0.76±0.18 |
| t值 | 8.510 | 8.096 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | miR-370-3p | miR-152-5p |
|---|---|---|---|
| 正常对照组 | 108 | 1.00±0.26 | 1.00±0.25 |
| 卵巢癌组 | 108 | 0.75±0.16 | 0.76±0.18 |
| t值 | 8.510 | 8.096 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | 年龄 | 肿瘤直径 | FIGO分期 | ||||
|---|---|---|---|---|---|---|---|---|
| ≤50岁/ [例(%)] | >50岁/ [例(%)] | ≥5 cm/ [例(%)] | <5 cm/ [例(%)] | Ⅰ~Ⅱ期/ [例(%)] | Ⅲ~Ⅳ期/ [例(%)] | |||
| 高表达组 | 54 | 22(52.38) | 32(48.48) | 27(42.86) | 27(60.00) | 30(76.92) | 24(34.78) | |
| 低表达组 | 54 | 20(47.62) | 34(51.52) | 36(57.14) | 18(40.00) | 9(23.08) | 45(65.22) | |
| χ2值 | 0.156 | 3.086 | 17.699 | |||||
| P值 | 0.693 | 0.079 | <0.001 | |||||
| 组别 | 病理类型 | 分化程度 | 淋巴转移/[例(%)] | 腹水/[例(%)] | ||||
| 浆液性/ [例(%)] | 其他类型/ [例(%)] | 低分化/ [例(%)] | 中高分化/ [例(%)] | |||||
| 高表达组 | 19(29.23) | 35(81.40) | 30(41.67) | 24(66.67) | 28(39.44) | 24(34.29) | ||
| 低表达组 | 46(70.77) | 8(18.60) | 42(58.33) | 12(33.33) | 43(60.56) | 46(65.71) | ||
| χ2值 | 28.169 | 6.000 | 9.250 | 19.651 | ||||
| P值 | <0.001 | 0.014 | 0.002 | <0.001 | ||||
| 组别 | 例数 | 年龄 | 肿瘤直径 | FIGO分期 | ||||
|---|---|---|---|---|---|---|---|---|
| ≤50岁/ [例(%)] | >50岁/ [例(%)] | ≥5 cm/ [例(%)] | <5 cm/ [例(%)] | Ⅰ~Ⅱ期/ [例(%)] | Ⅲ~Ⅳ期/ [例(%)] | |||
| 高表达组 | 54 | 22(52.38) | 32(48.48) | 27(42.86) | 27(60.00) | 30(76.92) | 24(34.78) | |
| 低表达组 | 54 | 20(47.62) | 34(51.52) | 36(57.14) | 18(40.00) | 9(23.08) | 45(65.22) | |
| χ2值 | 0.156 | 3.086 | 17.699 | |||||
| P值 | 0.693 | 0.079 | <0.001 | |||||
| 组别 | 病理类型 | 分化程度 | 淋巴转移/[例(%)] | 腹水/[例(%)] | ||||
| 浆液性/ [例(%)] | 其他类型/ [例(%)] | 低分化/ [例(%)] | 中高分化/ [例(%)] | |||||
| 高表达组 | 19(29.23) | 35(81.40) | 30(41.67) | 24(66.67) | 28(39.44) | 24(34.29) | ||
| 低表达组 | 46(70.77) | 8(18.60) | 42(58.33) | 12(33.33) | 43(60.56) | 46(65.71) | ||
| χ2值 | 28.169 | 6.000 | 9.250 | 19.651 | ||||
| P值 | <0.001 | 0.014 | 0.002 | <0.001 | ||||
| 组别 | 例数 | 年龄 | 肿瘤直径 | FIGO分期 | ||||
|---|---|---|---|---|---|---|---|---|
| ≤50岁/ [例(%)] | >50岁/ [例(%)] | ≥5 cm/ [例(%)] | <5 cm/ [例(%)] | Ⅰ~Ⅱ期/ [例(%)] | Ⅲ~Ⅳ期/ [例(%)] | |||
| 高表达组 | 55 | 25(59.42) | 30(45.45) | 35(55.56) | 20(44.44) | 32(82.05) | 7(17.95) | |
| 低表达组 | 53 | 17(40.48) | 36(54.55) | 28(44.44) | 25(55.56) | 23(33.33) | 46(66.67) | |
| χ2值 | 2.033 | 1.297 | 23.663 | |||||
| P值 | 0.154 | 0.255 | <0.001 | |||||
| 组别 | 病理类型 | 分化程度 | 淋巴转移/[例(%)] | 腹水/[例(%)] | ||||
| 浆液性/ [例(%)] | 其他类型/ [例(%)] | 低分化/ [例(%)] | 中高分化/ [例(%)] | |||||
| 高表达组 | 21(32.31) | 34(20.93) | 29(40.28) | 26(72.22) | 30(42.25) | 26(37.14) | ||
| 低表达组 | 44(67.69) | 9(20.93) | 43(59.72) | 10(27.78) | 41(57.75) | 44(62.86) | ||
| χ2值 | 22.644 | 9.800 | 6.237 | 15.123 | ||||
| P值 | <0.001 | 0.002 | 0.013 | <0.001 | ||||
| 组别 | 例数 | 年龄 | 肿瘤直径 | FIGO分期 | ||||
|---|---|---|---|---|---|---|---|---|
| ≤50岁/ [例(%)] | >50岁/ [例(%)] | ≥5 cm/ [例(%)] | <5 cm/ [例(%)] | Ⅰ~Ⅱ期/ [例(%)] | Ⅲ~Ⅳ期/ [例(%)] | |||
| 高表达组 | 55 | 25(59.42) | 30(45.45) | 35(55.56) | 20(44.44) | 32(82.05) | 7(17.95) | |
| 低表达组 | 53 | 17(40.48) | 36(54.55) | 28(44.44) | 25(55.56) | 23(33.33) | 46(66.67) | |
| χ2值 | 2.033 | 1.297 | 23.663 | |||||
| P值 | 0.154 | 0.255 | <0.001 | |||||
| 组别 | 病理类型 | 分化程度 | 淋巴转移/[例(%)] | 腹水/[例(%)] | ||||
| 浆液性/ [例(%)] | 其他类型/ [例(%)] | 低分化/ [例(%)] | 中高分化/ [例(%)] | |||||
| 高表达组 | 21(32.31) | 34(20.93) | 29(40.28) | 26(72.22) | 30(42.25) | 26(37.14) | ||
| 低表达组 | 44(67.69) | 9(20.93) | 43(59.72) | 10(27.78) | 41(57.75) | 44(62.86) | ||
| χ2值 | 22.644 | 9.800 | 6.237 | 15.123 | ||||
| P值 | <0.001 | 0.002 | 0.013 | <0.001 | ||||
| 组别 | 例数 | miR-370-3p | miR-152-5p |
|---|---|---|---|
| 存活组 | 76 | 0.82±0.18 | 0.83±0.17 |
| 死亡组 | 32 | 0.58±0.12 | 0.59±0.13 |
| t值 | 6.914 | 7.147 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | miR-370-3p | miR-152-5p |
|---|---|---|---|
| 存活组 | 76 | 0.82±0.18 | 0.83±0.17 |
| 死亡组 | 32 | 0.58±0.12 | 0.59±0.13 |
| t值 | 6.914 | 7.147 | |
| P值 | <0.001 | <0.001 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/ % | 特异性/ % | Youden指数 |
|---|---|---|---|---|---|
| miR-370-3p | 0.780(0.691~0.869) | 0.73 | 68.80 | 71.10 | 0.399 |
| miR-152-5p | 0.779(0.688~0.870) | 0.70 | 65.60 | 68.40 | 0.340 |
| 联合 检测 | 0.897(0.840~0.953) | 0.23 | 96.90 | 69.70 | 0.666 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/ % | 特异性/ % | Youden指数 |
|---|---|---|---|---|---|
| miR-370-3p | 0.780(0.691~0.869) | 0.73 | 68.80 | 71.10 | 0.399 |
| miR-152-5p | 0.779(0.688~0.870) | 0.70 | 65.60 | 68.40 | 0.340 |
| 联合 检测 | 0.897(0.840~0.953) | 0.23 | 96.90 | 69.70 | 0.666 |
| 项目 | 单因素分析 | 多因素分析 | ||
|---|---|---|---|---|
| HR值(95%CI) | P值 | HR值(95%CI) | P值 | |
| 年龄 | 1.389(0.934~2.064) | 0.104 | ||
| 肿瘤直径 | 1.527(0.932~2.502) | 0.093 | ||
| FIGO分期 | 1.852(1.130~3.035) | 0.014 | 2.376(0.924~6.111) | 0.073 |
| 病理类型 | 1.769(1.079~2.899) | 0.024 | 2.273(0.884~5.846) | 0.088 |
| 分化程度 | 1.931(1.111~3.356) | 0.020 | 2.392(0.930~6.152) | 0.070 |
| 淋巴结转移 | 1.843(1.060~3.203) | 0.030 | 2.271(0.883~5.841) | 0.089 |
| 腹水 | 1.974(1.136~3.431) | 0.016 | 2.516(0.978~6.471) | 0.056 |
| miR-370-3p | 0.894(0.840~0.952) | <0.001 | 0.883(0.829~0.940) | <0.001 |
| miR-152-5p | 0.956(0.934~0.979) | <0.001 | 0.806(0.714~0.910) | <0.001 |
| 项目 | 单因素分析 | 多因素分析 | ||
|---|---|---|---|---|
| HR值(95%CI) | P值 | HR值(95%CI) | P值 | |
| 年龄 | 1.389(0.934~2.064) | 0.104 | ||
| 肿瘤直径 | 1.527(0.932~2.502) | 0.093 | ||
| FIGO分期 | 1.852(1.130~3.035) | 0.014 | 2.376(0.924~6.111) | 0.073 |
| 病理类型 | 1.769(1.079~2.899) | 0.024 | 2.273(0.884~5.846) | 0.088 |
| 分化程度 | 1.931(1.111~3.356) | 0.020 | 2.392(0.930~6.152) | 0.070 |
| 淋巴结转移 | 1.843(1.060~3.203) | 0.030 | 2.271(0.883~5.841) | 0.089 |
| 腹水 | 1.974(1.136~3.431) | 0.016 | 2.516(0.978~6.471) | 0.056 |
| miR-370-3p | 0.894(0.840~0.952) | <0.001 | 0.883(0.829~0.940) | <0.001 |
| miR-152-5p | 0.956(0.934~0.979) | <0.001 | 0.806(0.714~0.910) | <0.001 |
| [1] |
刘蓉, 王德刚. 卵巢癌组织中SIRT-1、CD44的表达及临床意义[J]. 检验医学, 2022, 37(7):632-635.
DOI |
| [2] | WANG K, HE H, FENG X. Construction of metabolic molecular classification and immune characteristics for the prognosis prediction of ovarian cancer[J]. J Immunol Res, 2022, 2022:2359349. |
| [3] |
WANG X, LI X, WANG X. Identification of immune microenvironment subtypes that predicted the prognosis of patients with ovarian cancer[J]. J Cell Mol Med, 2021, 25(8):4053-4061.
DOI PMID |
| [4] | ZHAO L, LIANG X, WANG L, et al. The role of miRNA in ovarian cancer:an overview[J]. Reprod Sci, 2022, 29(10):2760-2767. |
| [5] | MAO J, WANG L, WU J, et al. MiR-370-3p as a novel biomarker promotes breast cancer progression by targeting FBLN5[J]. Stem Cells Int, 2021, 2021:4649890. |
| [6] |
YOU W, ZHANG X, JI M, et al. MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells[J]. Int J Biol Sci, 2018, 14(6):644-653.
DOI PMID |
| [7] | 中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(第四版)[J]. 中国实用妇科与产科杂志, 2018, 34(7):739-749. |
| [8] | ZHANG R, SIU M K Y, NGAN H Y S, et al. Molecular biomarkers for the early detection of ovarian cancer[J]. Int J Mol Sci, 2022, 23(19):12041. |
| [9] | SATHIPATI S Y, HO S Y. Identification of the miRNA signature associated with survival in patients with ovarian cancer[J]. Aging(Albany NY), 2021, 13(9):12660-12690. |
| [10] |
WU F, ZHOU J. CircAGFG1 promotes cervical cancer progression via miR-370-3p/RAF1 signaling[J]. BMC Cancer, 2019, 19(1):1067.
DOI PMID |
| [11] | LIN L, WANG D, QU S, et al. MiR-370-3p alleviates ulcerative colitis-related colorectal cancer in mice through inhibiting the inflammatory response and epithelial-mesenchymal transition[J]. Drug Des Devel Ther, 2020, 14:1127-1141. |
| [12] | ZHANG R, WANG J, JIA E, et al. LncRNA BCAR4 sponges miR-370-3p to promote bladder cancer progression via Wnt signaling[J]. Int J Mol Med, 2020, 45(2):578-588. |
| [13] | 武红, 李枫, 张曦辉, 等. miR-370-3p靶向HDAC4调节卵巢癌SKOV3细胞的生长和代谢研究[J]. 中国肿瘤临床, 2020, 47(23):1194-1199. |
| [14] |
KONG S, FANG Y, WANG B, et al. MiR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7[J]. J Cell Mol Med, 2020, 24(8):4569-4579.
DOI PMID |
| [15] | LYU M, LI X, SHEN Y, et al. CircATRNL1 and circZNF608 inhibit ovarian cancer by sequestering miR-152-5p and encoding protein[J]. Front Genet, 2022, 13:784089. |
| [16] | ZHAO X, ZHOU H B, LIU J, et al. Apigenin suppresses proliferation,invasion,and epithelial-mesenchymal transition of cervical carcinoma cells by regulation of miR-152/BRD4 axis[J]. Kaohsiung J Med Sci, 2021, 37(7):583-593. |
| [17] | 张旭, 魏华华, 王伟, 等. 非小细胞肺癌血清外泌体miR-152-5p和AGAP2-AS1水平变化及其预后评估价值[J]. 西部医学, 2021, 33(12):1844-1848. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||